文献速递乳腺癌放疗放疗物理与技术

丹麦乳腺癌协作组RT Natural试验的放疗质量保证

Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-23

该研究分析了DBCG RT Natural试验中238例接受部分乳腺照射(PBI)患者的放疗质量保证数据,评估靶区覆盖和危及器官剂量是否符合方案标准。结果显示靶区覆盖稳健,CTVp_PBI的V95%中位数为100%,仅1%低于95%;心脏和肺部剂量低,未违反剂量指导。

要点

  • 238例PBI患者中位V95%:瘤床和CTVp_PBI为100%,PTVp_PBI为98%。
  • 仅1%患者CTVp_PBI的V95%低于95%,22%患者PTVp_PBI的V95%低于95%。
  • 患侧肺平均剂量1.52 Gy,心脏平均剂量左侧0.25 Gy、右侧0.12 Gy,无剂量指导违反。

核心结论

  • DBCG RT Natural试验中的PBI提供了稳健的靶区覆盖,高剂量体积小,心脏和肺部剂量低,符合方案计划目标。

研究设计与样本

  • 对DBCG RT Natural试验中接受PBI的238例患者的前瞻性收集的DICOM-RT治疗计划进行方案依从性评估。

主要发现

  • 瘤床和CTVp_PBI的V95%中位数为100%,PTVp_PBI为98%;仅1%患者CTVp_PBI的V95%低于95%,22%患者PTVp_PBI的V95%低于95%。
  • 无患者超过处方剂量的110%;全乳V40Gy中位数为21%。
  • 患侧肺平均剂量中位数为1.52 Gy,心脏平均剂量中位数左侧0.25 Gy、右侧0.12 Gy,无剂量指导违反。
  • 呼吸门控未显著影响肺或心脏剂量。

关键数值与推荐

  • PBI处方剂量为40 Gy分15次。
  • CTVp_PBI的V95% intended最低为95%;PTVp_PBI的V95%低于95%者占22%。
  • 剂量指导未违反:患侧肺平均剂量1.52 Gy,心脏平均剂量左侧0.25 Gy、右侧0.12 Gy。

临床怎么用

  • 在实施PBI时,应确保靶区覆盖达到方案标准,并保持心脏和肺部剂量在低水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Partial breast irradiation (PBI) is standard for selected relatively low-risk breast cancer patients, aiming to minimise late effects while maintaining local control. The Danish Breast Cancer Group (DBCG) RT Natural trial investigated whether PBI could be safely omitted in selected patients. Here, we report the radiotherapy quality assurance in the trial, evaluating target coverage and doses to organs of interest against protocol criteria. MATERIAL/METHODS: Eligible patients were women ≥ 60 years with T ≤ 20 mm, unilateral, unifocal, node-negative, hormone receptor-positive, HER2-normal, non-lobular invasive breast cancer. Patients were randomised 1:1 to PBI (40 Gy in 15 fractions) versus no radiotherapy. Treatment plans for all patients treated with PBI were prospectively collected in a centralised DICOM-RT database and evaluated for protocol compliance. RESULTS: Data from the 238 patients receiving PBI were analysed. Dose coverage was high, with median V95% of 100% for the tumour bed and CTVp_PBI and 98% for the PTVp_PBI. Only 1% had a CTVp_PBI V95% below the intended 95%, whereas 22% had a PTVp_PBI V95% <95%. No patients exceeded 110% of the prescribed dose. Dose conformity was good with median whole-breast V40Gy of 21%.Ipsilateral median mean lung dose was 1.52 Gy, and median mean heart dose 0.25 Gy left / 0.12 Gy right with no violation of dose guidance. Respiratory gating did not significantly affect lung or heart doses. CONCLUSION: PBI in the DBCG RT Natural trial provided robust target coverage with minimal high-dose volumes, and maintained low cardiac and pulmonary doses, consistent with protocol planning objectives.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Høgsbjerg KW, Thomsen MS, Boye K, et al. Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial. Clin Transl Radiat Oncol. 2026. PMID: 42291796. doi:10.1016/j.ctro.2026.101190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。